Subject-specific tumor inhibiting cells and the use thereof
US11766455B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 14, 2018 |
| Grant date | Sep 26, 2023 |
| Priority date | — |
| Expiry date | May 17, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b−/− TICs). The Cbl-b−/− TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.